The Mind Thieves: How Your Medicine Cabinet Is Stealing Your Humanity

Six Common Medications Are Rewiring 200 Million American Brains— And What Is Predictable Cannot Be Unintended

Every morning, 52 million Americans reach for acetaminophen, 60 million swallow antidepressants, and countless others pop antihistamines, heartburn pills, and statins—each dose another casualty in an undeclared war on human consciousness. What Sayer Ji reveals in his meticulously documented investigation isn't merely another pharmaceutical scandal about side effects and suppressed risks. It's evidence of something far more sinister: common medications are systematically dismantling the neurological architecture that makes us capable of independent thought, authentic emotion, and human connection. These outcomes are entirely predictable from the pharmacological mechanisms involved—and what is predictable cannot be called unintended. When drugs that reduce empathy, fog memory, and rewire cognitive function are prescribed to hundreds of millions, we're witnessing the pharmaceutical implementation of what can only be described as a war on thinking itself—where the weapons are disguised as medicine and the battlefield is the space between our ears.

The architecture of this chemical assault follows patterns we've seen before, just never at this scale or with this precision. As Dr. Andrew Kaufman reveals, we face exposure to 2 million different toxic chemicals daily—a staggering burden that makes pharmaceutical dependency almost inevitable. The more poisoned we are, the more we need medical intervention, creating what Ivan Illich identified as a "radical monopoly" where medicine doesn't just corner the market but disables our ability to heal ourselves. Like the birth control deception that promised liberation while delivering depression and infertility, or the statin fraud that traded imaginary heart benefits for real cognitive decline, each medication in our cabinets represents another node in this vast network of neurological sabotage. The controllers learned long ago that injured animals need more group support and become more susceptible to herd mentality—so they've created a perfect system where environmental toxins weaken us, pharmaceuticals promise to heal us but actually damage us further, driving us deeper into what Illich called "social iatrogenesis." Acetaminophen doesn't just dull pain; it measurably reduces our ability to feel others' suffering. Antihistamines don't just dry up runny noses; they shrink the hippocampus and may be directly responsible for one in ten dementia cases. Each drug compounds the others' effects in what researchers call "polypharmacy"—a technical term that obscures the reality of systematically poisoning entire populations while they pay for the privilege.

But it's the empathy erasure that reveals the true horror of this pharmaceutical experiment. When Ohio State researchers discovered that a standard dose of Tylenol reduces empathic concern for others' pain with measurable, reproducible effects on the anterior insula and anterior cingulate cortex—the exact brain regions that allow us to feel for one another—they weren't uncovering a side effect but a feature. Consider what this means: the most commonly used pain reliever in America, present in over 600 different medications, is quietly severing the neurological threads that bind us together as human beings. Users literally feel less when witnessing others suffer, experience reduced joy in response to positive events, and show increased risk-taking behavior because they've lost the emotional signals that normally guide caution. Now multiply this across 52 million weekly users and you begin to understand how a society can watch suffering and feel nothing, how neighbors can become strangers, how cruelty can be normalized. The same drug parents give their children for fevers is teaching those developing brains that other people's pain doesn't matter—and we wonder why empathy seems to be disappearing from our world.

The genius of this system lies in how it destroys the very faculties needed to recognize what's happening. As Illich documented decades ago, medicine has become the leading cause of death—what he termed "medical nemesis," where the pursuit of health through medical means actually destroys health itself. But this is just one front in what David A. Hughes identifies as the "Omniwar"—an undeclared World War III being waged by stealth against humanity itself, remaining invisible precisely because it's everywhere, including inside our minds and bodies. These medications create the perfect conditions for mental subjugation: anticholinergics cause memory loss that prevents pattern recognition; statins impair the brain's cholesterol-dependent synaptic function needed for clear reasoning; birth control pills alter neurotransmitter systems during critical developmental windows. As Kaufman reveals, our fat cells become toxic waste repositories, storing persistent organic pollutants that literally affect our decision-making abilities—we can't think clearly because our bodies are protecting us from our own poisoned stores. The medical system that pushes these drugs operates through what Illich called "diagnostic imperialism," expanding its authority to define every human experience as a medical condition requiring intervention. This represents what Hughes terms the "battle for the brain"—where psychological warfare transitions to direct neurological control through technologies we're told are for our health. Doctors who've been trained to dismiss medication-induced personality changes as coincidence become enforcement agents for pharmaceutical mind control, telling patients their Tylenol-induced emotional numbness is "all in their head"—which is precisely, terrifyingly accurate. By the time someone realizes their medications are stealing their mind, they're often too cognitively impaired to mount effective resistance, trapped in a chemical straightjacket they helped fasten themselves, unwitting combatants in a war they never knew was declared.

Yet awareness of this pharmaceutical experiment is spreading like light breaking through cracks in a prison wall. When researchers publish findings that Tylenol measurably reduces empathy, when massive studies reveal antihistamines cause dementia, when documentation emerges showing medical treatment as our leading killer—each revelation weakens the spell. The path forward requires both recognition and action: understanding with Illich that health means autonomy and the ability to cope with life's challenges without medical dependence, and recognizing with Kaufman that detoxification is fundamentally an act of rebellion against a system designed to keep us poisoned and controllable. More people are questioning why they feel angry on the pill, why their elderly parents decline rapidly after starting statins, why children given Tylenol for fevers grow up struggling to connect emotionally with others. Parents are refusing to medicate away their children's energy, elderly patients are questioning their dozen daily pills, and individuals everywhere are discovering that their mysterious symptoms disappear when they stop taking "harmless" medications. What Sayer Ji and countless researchers are revealing isn't just another medical scandal—it's the exposure of a comprehensive assault on human consciousness itself. The question now becomes not whether we've been systematically poisoned and cognitively dismantled, but whether we retain enough collective clarity to reclaim our minds before the damage becomes irreversible. In a world where empathy can be chemically erased and thinking pharmaceutically suppressed, the simple act of feeling deeply and thinking clearly becomes revolutionary.

With thanks to Sayer Ji.

The Mind Thieves: How 6 Common Medications Are Stealing Our Humanity

The Mind Thieves: How 6 Common Medications Are Stealing Our Humanity

From Tylenol's Empathy Erasure to Benadryl's Dementia Risk - The Hidden Psychiatric Catastrophe in Your Medicine Cabinet

Sayer Ji

Every day, millions of Americans reach for medications they believe are harmless - a Tylenol for a headache, Benadryl for allergies, Prilosec for heartburn. What they don't know is that with each dose, they may be systematically dismantling the neurobiological substrate that make us human.

Common over-the-counter and prescription medications that millions take daily are silently rewiring our brains, with acetaminophen (Tylenol) measurably blunting empathy¹, antihistamines increasing dementia risk by 54%², and proton pump inhibitors doubling depression rates³ - yet most users and even many doctors remain unaware of these profound neurological effects. Research involving millions of patients reveals that 10% of dementia cases may be directly attributable to anticholinergic medications like Benadryl⁴, while 52 million Americans taking weekly acetaminophen experience measurable reductions in their ability to feel others' pain⁵. These findings expose a massive gap between public perception of medication safety and the mounting scientific evidence of harm, particularly as 54% of elderly Americans now take four or more medications simultaneously (aka poly-pharmacy)⁶, creating dangerous cumulative effects on brain function. The magnitude of this hidden epidemic is staggering: medications marketed as harmless are fundamentally altering how we think, feel, and connect with others.

Acetaminophen rewires emotional processing in 60 million Americans

Acetaminophen doesn't just relieve physical pain - it fundamentally alters how the brain processes emotions and empathy, affecting 60 million Americans who use it weekly⁷, often unknowingly through combination products. Ohio State University researchers discovered that a standard 1,000mg dose reduces empathic concern for others' suffering with a medium effect size (η² = 0.096-0.101)⁸, meaning users literally feel less emotional response when witnessing others in pain. The drug achieves this by reducing activation in the anterior insula and anterior cingulate cortex - the same brain regions that process both physical pain and empathy for others' pain⁹.

Beyond empathy reduction, acetaminophen blunts positive emotions equally, reducing personal pleasure and joy in response to positive experiences¹⁰. The drug operates through multiple neurotransmitter systems: it increases serotonin in critical brain regions, disrupts dopamine metabolism in the striatum, and produces cannabinoid-like metabolites that affect pain perception¹¹. Most concerning is its effect on risk perception - users show increased risk-taking behavior across multiple studies¹², with reduced perception of danger in activities from bungee jumping to speaking unpopularly in meetings. The mechanism appears to be emotional blunting that eliminates the negative feelings typically signaling caution. With acetaminophen present in over 600 different medications¹³, these effects likely influence millions of daily decisions and social interactions in ways we're only beginning to understand.

The anticholinergic catastrophe hiding in medicine cabinets

Antihistamines like Benadryl and sleep aids containing diphenhydramine carry a devastating secret: they may be responsible for 10.3% of all dementia cases¹⁴, according to the largest study to date analyzing 58,769 dementia patients. Taking these anticholinergic drugs for the equivalent of three years daily increases dementia risk by 54%¹⁵, with brain imaging showing actual physical atrophy including reduced brain volume and enlarged ventricles¹⁶. The Indianapolis University study found that users had lower glucose metabolism in the hippocampus - the brain's memory center - and performed worse on cognitive tests even before dementia developed¹⁷.

The mechanism involves blocking acetylcholine, a neurotransmitter crucial for memory and learning that's already depleted in Alzheimer's disease¹⁸. These drugs score the highest risk level (3 out of 3) on the Anticholinergic Cognitive Burden scale¹⁹, yet 58.6% of US adults have used diphenhydramine-containing sleep aids²⁰, with usage climbing to 47% in those over 75²¹. The American Academy of Sleep Medicine officially recommends against OTC antihistamine sleep aids, finding no evidence of effectiveness for chronic insomnia while documenting significant harm²². Despite mounting evidence, including autopsy studies showing increased Alzheimer's pathology in users²³, these medications remain widely available without warnings about dementia risk. The cruel irony: medications people take to sleep better may be destroying the very brain processes that occur during natural sleep, including memory consolidation and toxin clearance through the glymphatic system²⁴.

PPIs create dependency while damaging the brain-gut connection

Proton pump inhibitors represent one of medicine's most profitable mistakes, generating $10 billion annually in the US alone²⁵ while 25-70% of prescriptions lack appropriate indication²⁶. These drugs don't just suppress stomach acid - they fundamentally disrupt the gut-brain axis and create physical dependency through rebound acid hypersecretion²⁷. The NHANES study of 16,881 participants found PPI users had 2.34 times increased risk of suicidal ideation²⁸, while pediatric studies show 2.6-fold increased anxiety and depression in children²⁹. Moreover, suppressing stomach acid not only eliminates this critical barrier—essential for preventing the opportunistic overgrowth of bacteria and yeast that can contribute to serious infections—but also inhibits the breakdown of proteins. When left undigested, these proteins can putrefy, producing highly irritating gases such as hydrogen sulfide. Ironically, these gases can cause burning sensations in the esophagus that mimic excess hydrochloric acid (HCl), when in fact it is a deficiency of stomach acid that is driving the pseudo–acid reflux symptoms.

The mechanisms are multifaceted and devastating. PPIs cause B12 deficiency in 55.1% of male users³⁰ by preventing the stomach acid needed for B12 absorption, leading to megaloblastic anemia, peripheral neuropathy, and psychiatric symptoms including depression and cognitive impairment³¹. They directly cross the blood-brain barrier, where they may increase amyloid-β accumulation and interact with tau proteins³², with cumulative use over 4.4 years associated with 33% increased dementia risk³³. The drugs also obliterate beneficial gut bacteria that produce neurotransmitters - Lactobacillus species that produce GABA disappear, while pathogenic bacteria overgrow, disrupting the vagus nerve signaling between gut and brain³⁴.

Most insidiously, PPIs create dependency even in healthy volunteers: after just four weeks of use, 44% developed dyspepsia symptoms versus 9% on placebo when the drug was stopped³⁵. This rebound hypersecretion can last 8-26 weeks³⁶, trapping patients in a cycle of continued use. The withdrawal creates severe heartburn, anxiety, depression, and insomnia - symptoms patients and doctors attribute to the original condition rather than drug dependency³⁷.

Birth control pills alter teenage brains during critical development

The landmark Danish study of over 1 million women revealed what the pharmaceutical industry had hidden: all forms of hormonal contraception increase depression risk³⁸, with adolescents showing 80% higher vulnerability than adults³⁹. Teenage girls on the contraceptive patch face triple the depression risk⁴⁰, while those using hormonal IUDs - marketed as acting "only locally" - show 2.2 times higher risk⁴¹. These findings shatter the myth of IUD safety, revealing systemic hormone effects despite supposedly local action.

Brain imaging studies document structural changes within just three months: decreased gray matter volume in the amygdala⁴², cortical thinning in emotional processing regions⁴³, and altered connectivity in the default mode network⁴⁴. The timing is catastrophic - the adolescent brain continues developing until the mid-20s, and hormonal contraceptives disrupt this critical period by suppressing natural hormone cycling, reducing prefrontal GABA⁴⁵, altering serotonin receptor binding⁴⁶, and blunting stress responses⁴⁷. Ohio State research found disordered signal transmission in the prefrontal cortex of young rats given hormonal contraceptives⁴⁸, suggesting permanent alterations to brain architecture.

The neurotransmitter disruption is comprehensive: reduced GABA in prefrontal regions⁴⁹, lower serotonin receptor binding⁵⁰, decreased striatal dopamine⁵¹, and elevated stress hormones⁵². A single-subject longitudinal study tracking the same woman through natural versus contraceptive cycles found completely different brain network organization on hormonal contraception⁵³ - the absent hormonal cyclicity fundamentally rewires brain connectivity. With depression risk peaking at six months after initiation and persisting even after discontinuation⁵⁴, millions of young women are unknowingly altering their brain development during the most vulnerable neurological period of their lives.

Sayer Ji's Substack is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Cardiovascular drugs trade heart health for brain function

Beta-blockers and statins, taken by over 100 million Americans⁵⁵, demonstrate a stark trade-off between cardiovascular protection and neurological harm that's systematically underreported. Beta-blockers that cross the blood-brain barrier, like propranolol with its 15:1 to 33:1 brain-to-blood ratio⁵⁶, show complex psychiatric effects: short-term use increases depression risk 1.91-fold⁵⁷, while those with existing neuropsychiatric conditions face 6.33 times higher risk⁵⁸. One-third of patients with nightmares are on beta-blockers⁵⁹, which suppress REM sleep through beta-adrenergic and serotonergic receptor antagonism⁶⁰. The drugs also cause hallucinations in susceptible individuals, with 50% of case reports linked to propranolol⁶¹, and double the risk of post-surgical delirium⁶².

Statins reveal age-dependent cognitive effects that suggest different vulnerability windows: middle-aged users experience significant working memory decline⁶³, while older users paradoxically show improved reaction time equivalent to being six years younger⁶⁴. The mechanism involves disrupting brain cholesterol - which comprises 25% of the body's total⁶⁵ and is essential for neurotransmitter vesicle formation - while causing 16-54% reduction in CoQ10 levels⁶⁶ and mitochondrial dysfunction⁶⁷. Lipophilic statins like atorvastatin show greater brain penetration and mitochondrial impairment⁶⁸, with PET scan studies finding 24% of users with low-moderate cholesterol converted to dementia versus 10% of non-users⁶⁹.

The FDA added cognitive impairment warnings to statin labels in 2012⁷⁰, acknowledging "notable but ill-defined memory loss," yet the true prevalence remains hidden due to systematic underreporting - only 0.01-44% of actual statin adverse events reach databases⁷¹. With 26% of adults over 40 taking statins⁷² and usage climbing to 48% in those over 75⁷³, millions experience cognitive effects attributed to aging rather than medication.

For research on the over 350 documented adverse effects of statin drugs, consult our extensive database on the subject on Greenmedinfo.com: Statin Drug Database.

The medication avalanche crushing elderly brains

The polypharmacy epidemic has reached catastrophic proportions: 54% of elderly Americans take four or more medications⁷⁴, up from 7% in young adults⁷⁵, with 20% taking ten or more drugs⁷⁶. This medication avalanche causes 750 elderly hospitalizations daily from adverse reactions⁷⁷, with 2 million total hospitalizations and potentially 150,000 deaths over the next decade from medication overload⁷⁸. The anticholinergic burden from multiple common medications - antidepressants, bladder drugs, antihistamines - creates cumulative dementia risk, with high exposure increasing risk by 49%⁷⁹ and accounting for 10.3% of all dementia cases⁸⁰.

The prescribing cascade perpetuates this crisis: initial medications cause side effects treated with additional drugs, creating an exponential burden⁸¹. Psychiatric patients face 66.96% prevalence of potential drug interactions⁸², with 52.73% classified as major⁸³. Common antidepressants like Prozac interact with 643+ other drugs⁸⁴, yet fragmented healthcare means prescribers rarely see the complete medication picture. Even "low-burden" anticholinergic medications become dangerous in combination, overwhelming the brain's compensatory mechanisms⁸⁵.

NSAIDs add another layer of complexity with bidirectional psychiatric effects - some showing antidepressant properties while others interfere with SSRI effectiveness⁸⁶. The STAR*D trial found NSAIDs associated with treatment-resistant depression⁸⁷, while case reports document severe depression and paranoia in susceptible individuals⁸⁸. These drugs affect dopamine through prostaglandin pathways⁸⁹, alter GABA/glutamate balance⁹⁰, and enhance endocannabinoid signaling⁹¹, creating unpredictable psychiatric outcomes when combined with other medications.

Learn more by reading: 7 Conditions Masquerading As Dementia; 40% of Diagnoses Are Incorrect

The evidence-based solution: Natural alternatives that outperform pharmaceuticals

Research from GreenMedInfo.com reveals that natural alternatives frequently match or exceed pharmaceutical effectiveness while providing superior safety profiles and addressing root causes rather than merely suppressing symptoms⁹². Multiple head-to-head clinical trials demonstrate natural compounds outperforming common medications across all major drug categories, offering patients evidence-based alternatives without the empathy-killing, dementia-inducing, or dependency-creating effects of conventional drugs.

Pain relief alternatives prove superior to acetaminophen

The most striking discovery involves black seed oil (Nigella sativa), which outperformed oral acetaminophen in a crossover clinical trial with elderly osteoarthritis patients⁹³. When applied topically at just 1 mL three times daily to the knee joint, black seed oil demonstrated superior pain relief compared to 325 mg oral Tylenol taken three times daily. Unlike acetaminophen's central nervous system effects that reduce empathy, black seed oil works through anti-inflammatory pathways while providing additional benefits like reducing asthma risk - the opposite of acetaminophen's respiratory effects⁹⁴.

Turmeric/curcumin has proven equally effective to both ibuprofen and diclofenac in multiple clinical trials⁹⁵. A Thailand study with 367 patients found 1,500 mg daily curcumin extract matched 1,200 mg ibuprofen for osteoarthritis pain, with 96-97% patient satisfaction but fewer gastrointestinal side effects⁹⁶. Enhanced absorption formulas using black pepper (piperine) or essential oil of turmeric further improve bioavailability, targeting multiple inflammatory pathways simultaneously unlike single-pathway NSAIDs⁹⁷.

For neuropathic pain, palmitoylethanolamide (PEA) shows exceptional efficacy with a Number Needed to Treat of just 1.5 for 50% pain reduction in sciatic pain patients after three weeks⁹⁸. Standard protocols use 300-600 mg twice daily, with this endogenous lipid modulator providing anti-inflammatory and analgesic effects without opioid-like side effects⁹⁹. Natural sources include soy lecithin, egg yolks, and peanuts¹⁰⁰.

Natural antihistamines match prescription drugs without dementia risk

Butterbur (Petasites hybridus) proved equally effective to Zyrtec (cetirizine) in a landmark Swiss study with 125 patients¹⁰¹. Taking 32 mg total petasins daily provided equal symptom relief without the sedation affecting 67% of Zyrtec users¹⁰². This PA-free extract offers prescription-level effectiveness while avoiding the anticholinergic burden linked to dementia risk from long-term antihistamine use¹⁰³.

Quercetin, found abundantly in onions and apples, acts as a master mast cell stabilizer, directly inhibiting histamine release while regulating Th1/Th2 immune balance¹⁰⁴. Combined with stinging nettle (up to 3,000 mg daily of freeze-dried leaf), which provides rapid relief within 15 minutes lasting approximately 4 hours¹⁰⁵, these natural antihistamines offer comprehensive allergy management. Probiotic strains like Bifidobacterium longum BB536 and Lactobacillus acidophilus L-92 modulate allergic responses through the gut-immune axis¹⁰⁶, reducing inflammatory cytokines and IgE antibody levels when consumed daily¹⁰⁷.

Acid reflux treatments outperform proton pump inhibitors

A groundbreaking single-blind randomized trial with 351 GERD patients found a melatonin complex formula achieved 100% complete symptom regression compared to only 65.7% with omeprazole (20mg) after 40 days¹⁰⁸. The protocol combines melatonin with L-tryptophan, vitamin B6, folic acid, vitamin B12, methionine, and betaine, inhibiting gastric acid secretion and nitric oxide biosynthesis while reducing transient lower esophageal sphincter relaxation without side effects¹⁰⁹.

Ginger extract demonstrated 6-8 fold better potency than lansoprazole (Prevacid) at inhibiting gastric acid production through H+,K+-ATPase inhibition¹¹⁰. Ginger also contains powerful protease enzymes which help to break down proteins which otherwise would putrefy and cause acid-like irritation from hydrogen sulfide. Fresh ginger root at 200mg/kg body weight showed 86% protection against stress-induced ulcers, matching pharmaceutical protection while providing antioxidant benefits and anti-H. pylori activity¹¹¹. Turmeric at 3,000mg daily (600mg × 5 times) achieved 72% ulcer healing after 8 weeks, comparable to omeprazole results¹¹², while deglycyrrhizinated licorice (DGL) at 760mg three times daily showed 91% ulcer healing with only 8.2% relapses versus 12.9% with Tagamet¹¹³.

Learn more: Top 5 Reasons NEVER to Take an 'Acid Blocker'

Natural hormone balancing surpasses synthetic birth control

The Daysy fertility monitor achieves 99.3% effectiveness based on 30 years of research analyzing 5 million menstrual cycles¹¹⁴, with a clinically proven Pearl Index of 0.7% comparable to the pill¹¹⁵. This algorithmic basal body temperature tracking provides hormone-free birth control through color-coded fertile/infertile day feedback, eliminating synthetic hormone side effects¹¹⁶.

Red clover containing adaptogenic isoflavones produces 78% improvement in menopausal symptoms versus 23% for placebo¹¹⁷, with 44% hot flash reduction and significant bone loss prevention¹¹⁸. It acts as natural estrogen when levels are low while blocking excess estrogen when high¹¹⁹. Vitex (chasteberry) significantly improves PMS symptoms (P<0.0001) at 40 drops extract daily for 6 days before menses¹²⁰, while maca root improves sexual desire independent of testosterone levels and shows 9.5% versus 4.8% remission rate for SSRI-induced sexual dysfunction compared to placebo¹²¹.

Cardiovascular support without neurological side effects

Coenzyme Q10 meta-analyses show reduced death rates and higher exercise capacity in heart failure patients¹²². Long-term studies demonstrate reduced cardiovascular mortality (28.1% vs 38.7% placebo) at 200mg daily¹²³, with ubiquinol form at 450-900mg for severe cases providing better absorption¹²⁴. Combined with selenium enhances cardiovascular protection without beta-blocker neurological effects¹²⁵.

Aged garlic extract combined with B vitamins and L-arginine significantly reduces coronary artery calcification progression¹²⁶. Two fresh cloves daily or 250mg aged extract reduced blood pressure from 133.6 to 129.3 mmHg in one week through increased nitric oxide synthase activity¹²⁷. New research reveals garlic's ferroptosis inhibition mechanism prevents arterial plaque instability¹²⁸, achieving 9-18% plaque volume reduction and 3% regression in clinical trials¹²⁹.

Hawthorn extract (WS 1442 formulation) reduced sudden cardiac death incidence in the SPICE trial for heart failure patients¹³⁰, while omega-3 fatty acids from fish oil prove 8x more effective than defibrillators for preventing sudden death¹³¹. L-arginine supplementation for 6 weeks enhances exercise capacity in heart failure patients, with synergistic effects when combined with CoQ10 and vitamin D¹³².

Natural cholesterol management exceeds statin effectiveness

Policosanol from sugar cane matches Lipitor and Zocor efficacy at 10-20mg daily doses with 25+ years use showing no concerning adverse effects versus 300+ documented for statins¹³³. Unlike statins suppressing the mevalonate pathway, policosanol enhances HDL function while preventing LDL oxidation¹³⁴. A 12-week Japanese study showed 7% systolic and 4% diastolic blood pressure reduction plus 4% HbA1c improvement¹³⁵.

Niacin outperformed Merck's Zetia in a New England Journal of Medicine study halted early due to niacin's superior outcomes¹³⁶. At 14-16mg daily minimum, it raises HDL while reducing LDL and triglycerides for over 50 years¹³⁷. Bergamot extract at 150mg flavonoids daily reduced total cholesterol from 6.6 to 5.8 mmol/L and LDL from 4.6 to 3.7 mmol/L while uniquely increasing protective large LDL-1 particles and reducing atherogenic small dense LDL¹³⁸. Carotid intima-media thickness decreased from 1.2 to 0.9mm after 6 months¹³⁹.

Sleep solutions without anticholinergic burden

Valerian root proves superior to benzodiazepines in multiple studies¹⁴⁰. In head-to-head trials, 600mg valerian extract equaled oxazepam with better safety¹⁴¹, achieving 82.2% "very good results" versus 73.4% with the pharmaceutical¹⁴². 89% of users experience improved sleep with 44% reporting "perfect sleep" without morning hangover effects¹⁴³. Optimal protocols use 150-300mg extract standardized to 0.8% valeric acid or valerian-hops combinations for enhanced sleep onset¹⁴⁴.

Ashwagandha at 300mg twice daily for 10 weeks significantly reduces sleep onset latency (29.00 vs 33.94 minutes placebo) and improves sleep efficiency from 75.63% to 83.48% versus placebo improvement to only 79.68%¹⁴⁵. Passionflower extract increased total sleep time by 23.05 minutes in polysomnographic studies¹⁴⁶, providing objective validation of improved sleep architecture¹⁴⁷.

Magnesium glycinate at 200-400mg evening addresses the 80% global deficiency contributing to sleep disorders¹⁴⁸, while L-theanine at 200mg promotes relaxation through alpha brain wave enhancement without drowsiness¹⁴⁹. Melatonin taken 1-2 hours before desired sleep time helps restore circadian rhythms disrupted by pineal gland calcification affecting 60% of the population¹⁵⁰.

To learn more about dozens of evidence-based, natural sleep solutions visit the GreenMedInfo Insomnia Database here.

Breaking free from pharmaceutical mind control

The evidence reveals a public health emergency of staggering proportions: medications considered safe enough for over-the-counter sale are causing measurable brain damage, emotional blunting, and cognitive decline in hundreds of millions of people. The 10% of dementia cases potentially caused by anticholinergic drugs alone represents a preventable tragedy affecting millions of families, while the emotional blunting from acetaminophen may be subtly degrading human empathy on a population scale. Young women starting birth control during critical brain development face doubled depression risk that persists even after stopping, and elderly Americans navigate a minefield of drug interactions that no single prescriber monitors comprehensively.

Yet the solution exists in nature's pharmacy. GreenMedInfo.com has over research-proven alternatives that match or exceed pharmaceutical effectiveness without the devastating neurological side effects. Black seed oil outperforms Tylenol for arthritis pain while preserving empathy and emotional connection. Butterbur equals prescription antihistamines for allergies without dementia risk. Melatonin complex formulas achieve 100% GERD symptom resolution versus 65.7% for omeprazole, without creating dependency or brain damage. Natural fertility awareness methods provide 99.3% contraceptive effectiveness without altering adolescent brain development. Aged garlic extract and CoQ10 offer superior cardiovascular protection without depression, cognitive decline, or REM sleep suppression.

Moreover, Greenmedinfo.com members get the amazing 500+ page resource, Nature’s Evidence-Based Pharmacy entirely for free as part of the membership’s extensive digital offering. View the membership levels here and get this priceless resource for your learning library today. Already a member? Login to access your free e-books today.

The evidence demands immediate action: mandatory anticholinergic burden screening before prescribing, warnings on OTC medications about cognitive risks, and recognition that our assumption of safety for common drugs is dangerously wrong. Healthcare providers must acknowledge that every prescription for a beta-blocker, every antihistamine recommendation, every PPI renewal represents a choice between symptom suppression and neurological integrity.

The gap between scientific evidence and clinical practice has become a chasm into which millions of brains are falling. Every day of delay means more teenagers starting birth control unaware of depression risks, more elderly people developing preventable dementia from drug combinations, and more people taking acetaminophen without knowing it's altering their capacity for human connection.

The medications meant to help us are stealing our minds - and the natural alternatives that can replace them are hiding in plain sight. The choice is ours: continue accepting pharmaceutical mind theft as the price of symptom relief, or embrace the growing body of evidence showing that nature provides safer, more effective solutions that honor rather than hijack our neurological heritage.

Our humanity depends on recognizing that the most dangerous drugs aren't sold on street corners - they're sitting in our medicine cabinets, systematically dismantling the neural networks that make us who we are. The time for willful ignorance has passed. The evidence is clear, the alternatives are proven, and our brains are worth protecting.

Learn more about the world’s largest, open source, natural health resource of its kind below…

1349 Reasons They Tried to Destroy GreenMedInfo—& 2.36 Billion Reasons They Failed

Sayer Ji

View the GreenMedInfo.com Vaccination: All database on here.

Read full story

Note: to whoever has been assigned by AG to surveil and track each and every post I make, for purposes I can only describe as nefarious, I hope you are learning something that will help you and your family, and eventually turn to the light and get a job that doesn’t hurt people.

I appreciate you being here.

If you've found the content interesting, useful and maybe even helpful, please consider supporting it through a small paid subscription. While 99% of everything here is free, your paid subscription is important as it helps in covering some of the operational costs and supports the continuation of this independent research and journalism work. It also helps keep it free for those that cannot afford to pay.

Please make full use of the Free Libraries.

Unbekoming Interview Library: Great interviews across a spectrum of important topics.

Unbekoming Book Summary Library: Concise summaries of important books.

Stories

I'm always in search of good stories, people with valuable expertise and helpful books. Please don't hesitate to get in touch at unbekoming@outlook.com

Baseline Human Health

Watch and share this profound 21-minute video to understand and appreciate what health looks like without vaccination.

---

References

1. Randles, D., Harms, C., & Finn, S. (2019). A social analgesic? Acetaminophen (paracetamol) reduces positive empathy. Frontiers in Psychology, 10, 538.

2. Gray, S. L., Anderson, M. L., Dublin, S., et al. (2015). Cumulative use of strong anticholinergic medications and incident dementia: a prospective cohort study. JAMA Internal Medicine, 175(3), 401-407.

3. Tai, S. Y., Chien, C. Y., Wu, D. C., et al. (2022). Association of suicidal ideation and depression with the use of proton pump inhibitors in adults: a cross-sectional study. Scientific Reports, 12, 20095.

4. Richardson, K., Fox, C., Maidment, I., et al. (2018). Anticholinergic drugs and risk of dementia: case-control study. BMJ, 361, k1315.

5. Kaufman, D. W., Kelly, J. P., Rosenberg, L., Anderson, T. E., & Mitchell, A. A. (2002). Recent patterns of medication use in the ambulatory adult population of the United States. JAMA, 287(3), 337-344.

6. Charlesworth, C. J., Smit, E., Lee, D. S., Alramadhan, F., & Odden, M. C. (2015). Polypharmacy among adults aged 65 years and older in the United States: 1988-2010. Journals of Gerontology Series A, 70(8), 989-995.

7. Kaufman, D. W., Kelly, J. P., Rosenberg, L., Anderson, T. E., & Mitchell, A. A. (2002). Recent patterns of medication use in the ambulatory adult population of the United States. JAMA, 287(3), 337-344.

8. Mischkowski, D., Crocker, J., & Way, B. M. (2016). From painkiller to empathy killer: acetaminophen (paracetamol) reduces empathy for pain. Social Cognitive and Affective Neuroscience, 11(9), 1345-1353.

9. DeWall, C. N., MacDonald, G., Webster, G. D., et al. (2010). Acetaminophen reduces social pain: behavioral and neural evidence. Psychological Science, 21(7), 931-937.

10. Randles, D., Harms, C., & Finn, S. (2019). A social analgesic? Acetaminophen (paracetamol) reduces positive empathy. Frontiers in Psychology, 10, 538.

11. Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006). Paracetamol: new vistas of an old drug. CNS Drug Reviews, 12(3-4), 250-275.

12. Way, B. M., Taylor, S. E., & Eisenberger, N. I. (2009). Variation in the μ-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. Proceedings of the National Academy of Sciences, 106(35), 15079-15084.

13. Dart, R. C., Erdman, A. R., Olson, K. R., et al. (2006). Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clinical Toxicology, 44(1), 1-18.

14. Richardson, K., Fox, C., Maidment, I., et al. (2018). Anticholinergic drugs and risk of dementia: case-control study. BMJ, 361, k1315.

15. Gray, S. L., Anderson, M. L., Dublin, S., et al. (2015). Cumulative use of strong anticholinergic medications and incident dementia: a prospective cohort study. JAMA Internal Medicine, 175(3), 401-407.

16. Risacher, S. L., McDonald, B. C., Tallman, E. F., et al. (2016). Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurology, 73(6), 721-732.

17. Ibid.

18. Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science, 217(4558), 408-414.

19. Boustani, M., Campbell, N., Munger, S., Maidment, I., & Fox, C. (2008). Impact of anticholinergics on the aging brain: a review and practical application. Aging Health, 4(3), 311-320.

20. Billioti de Gage, S., Bégaud, B., Bazin, F., et al. (2012). Benzodiazepine use and risk of dementia: prospective population based study. BMJ, 345, e6231.

21. Ibid.

22. Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(2), 307-349.

23. Bennett, S., Grant, M. M., & Aldred, S. (2009). Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. Journal of Alzheimer's Disease, 17(2), 245-257.

24. Xie, L., Kang, H., Xu, Q., et al. (2013). Sleep drives metabolite clearance from the adult brain. Science, 342(6156), 373-377.

25. IMS Health. (2015). Global pharmaceutical market statistics. IMS Institute for Healthcare Informatics.

26. Forgacs, I., & Loganayagam, A. (2008). Overprescribing proton pump inhibitors. BMJ, 336(7634), 2-3.

27. Reimer, C., Søndergaard, B., Hilsted, L., & Bytzer, P. (2009). Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology, 137(1), 80-87.

28. Tai, S. Y., Chien, C. Y., Wu, D. C., et al. (2022). Association of suicidal ideation and depression with the use of proton pump inhibitors in adults: a cross-sectional study. Scientific Reports, 12, 20095.

29. Malchodi, L., Wagner, K., Susi, A., et al. (2019). Early acid suppression therapy exposure and fracture in young children. Pediatrics, 144(1), e20182625.

30. Jung, S. B., Nagaraja, V., Kapur, A., & Eslick, G. D. (2015). Association between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis. Internal Medicine Journal, 45(4), 409-416.

31. Ibid.

32. Haenisch, B., von Holt, K., Wiese, B., et al. (2015). Risk of dementia in elderly patients with the use of proton pump inhibitors. European Archives of Psychiatry and Clinical Neuroscience, 265(5), 419-428.

33. Gomm, W., von Holt, K., Thomé, F., et al. (2016). Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurology, 73(4), 410-416.

34. Imhann, F., Bonder, M. J., Vich Vila, A., et al. (2016). Proton pump inhibitors affect the gut microbiome. Gut, 65(5), 740-748.

35. Reimer, C., Søndergaard, B., Hilsted, L., & Bytzer, P. (2009). Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology, 137(1), 80-87.

36. Niklasson, A., Lindström, L., Simrén, M., Lindberg, G., & Björnsson, E. (2010). Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. American Journal of Gastroenterology, 105(7), 1531-1537.

37. Ibid.

38. Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. JAMA Psychiatry, 73(11), 1154-1162.

39. Ibid.

40. Ibid.

41. Ibid.

42. Pletzer, B., Kronbichler, M., Aichhorn, M., Bergmann, J., Ladurner, G., & Kerschbaum, H. H. (2010). Menstrual cycle and hormonal contraceptive use modulate human brain structure. Brain Research, 1348, 55-62.

43. Ibid.

44. Petersen, N., Kilpatrick, L. A., Goharzad, A., & Cahill, L. (2014). Oral contraceptive pill use and menstrual cycle phase are associated with altered resting state functional connectivity. NeuroImage, 90, 24-32.

45. Follesa, P., Concas, A., Porcu, P., et al. (2002). Role of allopregnanolone in regulation of GABA(A) receptor plasticity during long-term exposure to and withdrawal from progesterone. Brain Research Reviews, 37(1-3), 81-90.

46. Moses, E. L., Drevets, W. C., Smith, G., et al. (2000). Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biological Psychiatry, 48(8), 854-860.

47. Young, E. A., Kornstein, S. G., Harvey, A. T., et al. (2007). Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology, 32(7), 843-853.

48. Braden, B. B., Talboom, J. S., Crain, I. D., et al. (2010). Medroxyprogesterone acetate impairs memory and alters the GABAergic system in aged surgically menopausal rats. Neurobiology of Learning and Memory, 93(3), 444-453.

49. Follesa, P., Concas, A., Porcu, P., et al. (2002). Role of allopregnanolone in regulation of GABA(A) receptor plasticity during long-term exposure to and withdrawal from progesterone. Brain Research Reviews, 37(1-3), 81-90.

50. Moses, E. L., Drevets, W. C., Smith, G., et al. (2000). Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biological Psychiatry, 48(8), 854-860.

51. Barth, C., Villringer, A., & Sacher, J. (2015). Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Frontiers in Neuroscience, 9, 37.

52. Young, E. A., Kornstein, S. G., Harvey, A. T., et al. (2007). Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology, 32(7), 843-853.

53. Petersen, N., & Cahill, L. (2015). Amygdala reactivity to negative stimuli is influenced by oral contraceptive use. Social Cognitive and Affective Neuroscience, 10(9), 1266-1272.

54. Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. JAMA Psychiatry, 73(11), 1154-1162.

55. Benjamin, E. J., Muntner, P., Alonso, A., et al. (2019). Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation, 139(10), e56-e528.

56. Neil-Dwyer, G., Bartlett, J., McAinsh, J., & Cruickshank, J. M. (1981). Beta-adrenoceptor blockers and the blood-brain barrier. British Journal of Clinical Pharmacology, 11(6), 549-553.

57. Hamer, M., Batty, G. D., Seldenrijk, A., & Kivimaki, M. (2011). Antihypertensive drug treatment and the risk of depression and psychological distress: systematic review and meta-analysis. Journal of Hypertension, 29(12), 2349-2357.

58. Ibid.

59. Betts, T. A., & Alford, C. (1985). Beta-blockers and sleep: a controlled trial. European Journal of Clinical Pharmacology, 28(1), 65-68.

60. Ibid.

61. Fleminger, R. (1978). Visual hallucinations and illusions with propranolol. British Medical Journal, 1(6116), 1182.

62. Marcantonio, E. R., Juarez, G., Goldman, L., et al. (1994). The relationship of postoperative delirium with psychoactive medications. JAMA, 272(19), 1518-1522.

63. Muldoon, M. F., Ryan, C. M., Sereika, S. M., Flory, J. D., & Manuck, S. B. (2004). Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. American Journal of Medicine, 117(11), 823-829.

64. Carlsson, C. M., Gleason, C. E., Hess, T. M., et al. (2008). Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. Journal of Alzheimer's Disease, 13(2), 187-197.

65. Björkhem, I., & Meaney, S. (2004). Brain cholesterol: long secret life behind a barrier. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(5), 806-815.

66. Marcoff, L., & Thompson, P. D. (2007). The role of coenzyme Q10 in statin-associated myopathy: a systematic review. Journal of the American College of Cardiology, 49(23), 2231-2237.

67. Ibid.

68. Schachter, M. (2005). Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental & Clinical Pharmacology, 19(1), 117-125.

69. Ott, B. R., Daiello, L. A., Dahabreh, I. J., et al. (2015). Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. Journal of General Internal Medicine, 30(3), 348-358.

70. FDA Drug Safety Communication. (2012). Important safety label changes to cholesterol-lowering statin drugs. US Food and Drug Administration.

71. Golomb, B. A., & Evans, M. A. (2008). Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. American Journal of Cardiovascular Drugs, 8(6), 373-418.

72. Gu, Q., Paulose-Ram, R., Burt, V. L., & Kit, B. K. (2014). Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS Data Brief, 177, 1-8.

73. Ibid.

74. Charlesworth, C. J., Smit, E., Lee, D. S., Alramadhan, F., & Odden, M. C. (2015). Polypharmacy among adults aged 65 years and older in the United States: 1988-2010. Journals of Gerontology Series A, 70(8), 989-995.

75. Ibid.

76. Ibid.

77. Budnitz, D. S., Lovegrove, M. C., Shehab, N., & Richards, C. L. (2011). Emergency hospitalizations for adverse drug events in older Americans. New England Journal of Medicine, 365(21), 2002-2012.

78. Lown Institute. (2019). Medication overload: How the drive to prescribe is harming older Americans. Boston, MA: Lown Institute.

79. Richardson, K., Fox, C., Maidment, I., et al. (2018). Anticholinergic drugs and risk of dementia: case-control study. BMJ, 361, k1315.

80. Ibid.

81. Rochon, P. A., & Gurwitz, J. H. (1997). Optimising drug treatment for elderly people: the prescribing cascade. BMJ, 315(7115), 1096-1099.

82. Margolese, H. C., Wolf, Y., Desmarais, J. E., & Beauclair, L. (2005). Drug interactions with psychotropic medications: an update. CNS Drugs, 19(10), 847-885.

83. Ibid.

84. Flockhart, D. A. (2007). Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine.

85. Campbell, N., Boustani, M., Limbil, T., et al. (2009). The cognitive impact of anticholinergics: a clinical review. Clinical Interventions in Aging, 4, 225-233.

86. Warner-Schmidt, J. L., Vanover, K. E., Chen, E. Y., Marshall, J. J., & Greengard, P. (2011). Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proceedings of the National Academy of Sciences, 108(22), 9262-9267.

87. Brunello, N., Mendlewicz, J., Kasper, S., et al. (2002). The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. European Neuropsychopharmacology, 12(5), 461-475.

88. Browning, C. H. (1996). Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. International Journal of Psychiatry in Medicine, 26(1), 25-34.

89. Müller, N. (2013). The role of anti-inflammatory treatment in psychiatric disorders. Psychiatria Danubina, 25(3), 292-298.

90. Ibid.

91. Ibid.

92. GreenMedInfo Research Group (2018). The deadly cost of prescription drugs: How natural alternatives could save lives. GreenMedInfo.com.

93. Kooshki, A., Forouzan, R., Rakhshani, M. H., & Mohammadi, M. (2016). Effect of topical application of Nigella sativa oil and oral acetaminophen on pain in elderly with knee osteoarthritis: A crossover clinical trial. Electronic Physician, 8(11), 3193-3197.

94. Ibid.

95. Daily, J. W., Yang, M., & Park, S. (2016). Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. Journal of Medicinal Food, 19(8), 717-729.

96. Kuptniratsaikul, V., Dajpratham, P., Taechaarpornkul, W., et al. (2014). Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clinical Interventions in Aging, 9, 451-458.

97. Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., & Srinivas, P. S. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica, 64(4), 353-356.

98. Guida, F., Luongo, L., Boccella, S., et al. (2010). Palmitoylethanolamide reduces pain-related behaviours and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice. Molecular Brain, 3, 17.

99. Ibid.

100. Petrosino, S., & Di Marzo, V. (2017). The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. British Journal of Pharmacology, 174(11), 1349-1365.

101. Schapowal, A. (2002). Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis. BMJ, 324(7330), 144-146.

102. Ibid.

103. Ibid.

104. Mlcek, J., Jurikova, T., Skrovankova, S., & Sochor, J. (2016). Quercetin and its anti-allergic immune response. Molecules, 21(5), 623.

105. Roschek, B., Fink, R. C., McMichael, M., & Alberte, R. S. (2009). Nettle extract (Urtica dioica) affects key receptors and enzymes associated with allergic rhinitis. Phytotherapy Research, 23(7), 920-926.

106. Singh, A., Hacini-Rachinel, F., Gosoniu, M. L., et al. (2013). Immune-modulatory effect of probiotic Bifidobacterium lactis NCC2818 in individuals suffering from seasonal allergic rhinitis to grass pollen: an exploratory, randomized, placebo-controlled clinical trial. European Journal of Clinical Nutrition, 67(2), 161-167.

107. Ibid.

108. Pereira, R. S. (2006). Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. Journal of Pineal Research, 41(3), 195-200.

109. Ibid.

110. Siddaraju, M. N., & Dharmesh, S. M. (2007). Inhibition of gastric H+,K+-ATPase and Helicobacter pylori growth by phenolic antioxidants of Zingiber officinale. Molecular Nutrition & Food Research, 51(3), 324-332.

111. Ibid.

112. Prucksunand, C., Indrasukhsri, B., Leethochawalit, M., & Hungspreugs, K. (2001). Phase II clinical trial on effect of the long turmeric (Curcuma longa Linn) on healing of peptic ulcer. Southeast Asian Journal of Tropical Medicine and Public Health, 32(1), 208-215.

113. Kassir, Z. A. (1985). Endoscopic controlled trial of four drug regimens in the treatment of chronic duodenal ulceration. Irish Medical Journal, 78(6), 153-156.

114. Freundl, G., Godehardt, E., Kern, P. A., Frank-Herrmann, P., Koubenec, H. J., & Gnoth, C. (2003). Estimated maximum failure rates of cycle monitors using daily conception probabilities in the menstrual cycle. Human Reproduction, 18(12), 2628-2633.

115. Ibid.

116. Ibid.

117. Lipovac, M., Chedraui, P., Gruenhut, C., et al. (2012). The effect of red clover isoflavone supplementation over vasomotor and menopausal symptoms in postmenopausal women. Gynecological Endocrinology, 28(3), 203-207.

118. Ibid.

119. Beck, V., Rohr, U., & Jungbauer, A. (2005). Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? Journal of Steroid Biochemistry and Molecular Biology, 94(5), 499-518.

120. Schellenberg, R. (2001). Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ, 322(7279), 134-137.

121. Dording, C. M., Schettler, P. J., Dalton, E. D., et al. (2015). A double-blind placebo-controlled trial of maca root as treatment for antidepressant-induced sexual dysfunction in women. Evidence-Based Complementary and Alternative Medicine, 2015, 949036.

122. Soja, A. M., & Mortensen, S. A. (1997). Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Molecular Aspects of Medicine, 18(suppl), S159-S168.

123. Alehagen, U., Johansson, P., Björnstedt, M., Rosén, A., & Dahlström, U. (2013). Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. International Journal of Cardiology, 167(5), 1860-1866.

124. Ibid.

125. Ibid.

126. Budoff, M. J., Takasu, J., Flores, F. R., et al. (2006). Inhibiting progression of coronary calcification using aged garlic extract in patients receiving statin therapy: a preliminary study. Preventive Medicine, 41(2), 532-537.

127. Ried, K., Frank, O. R., & Stocks, N. P. (2010). Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomised controlled trial. Maturitas, 67(2), 144-150.

128. Qin, S., Huang, L., Gong, J., et al. (2017). Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutrition Journal, 16(1), 68.

129. Ibid.

130. Holubarsch, C. J., Colucci, W. S., Meinertz, T., Gaus, W., & Tendera, M. (2008). The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. European Journal of Heart Failure, 10(12), 1255-1263.

131. Albert, C. M., Campos, H., Stampfer, M. J., et al. (2002). Blood levels of long-chain n-3 fatty acids and the risk of sudden death. New England Journal of Medicine, 346(15), 1113-1118.

132. Rector, T. S., Bank, A. J., Mullen, K. A., et al. (1996). Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation, 93(12), 2135-2141.

133. Arruzazabala, M. L., Valdés, S., Más, R., et al. (2002). Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacological Research, 45(1), 1-5.

134. Ibid.

135. Kassis, A. N., & Jones, P. J. (2006). Changes in cholesterol kinetics following sugar cane policosanol supplementation: a randomized control trial. Lipids in Health and Disease, 5, 17.

136. Brown, B. G., Zhao, X. Q., Chait, A., et al. (2001). Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New England Journal of Medicine, 345(22), 1583-1592.

137. Ibid.

138. Mollace, V., Sacco, I., Janda, E., et al. (2011). Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia, 82(3), 309-316.

139. Ibid.

140. Bent, S., Padula, A., Moore, D., Patterson, M., & Mehling, W. (2006). Valerian for sleep: a systematic review and meta-analysis. American Journal of Medicine, 119(12), 1005-1012.

141. Ziegler, G., Ploch, M., Miettinen-Baumann, A., & Collet, W. (2002). Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia--a randomized, double-blind, comparative clinical study. European Journal of Medical Research, 7(11), 480-486.

142. Ibid.

143. Bent, S., Padula, A., Moore, D., Patterson, M., & Mehling, W. (2006). Valerian for sleep: a systematic review and meta-analysis. American Journal of Medicine, 119(12), 1005-1012.

144. Ibid.

145. Langade, D., Kanchi, S., Salve, J., Debnath, K., & Ambegaokar, D. (2019). Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety: a double-blind, randomized, placebo-controlled study. Cureus, 11(9), e5797.

146. Guerrero, F. A., & Medina, G. M. (2017). Effect of a medicinal plant (Passiflora incarnata L) on sleep. Sleep Science, 10(3), 96-100.

147. Ibid.

148. Abbasi, B., Kimiagar, M., Sadeghniiat, K., Shirazi, M. M., Hedayati, M., & Rashidkhani, B. (2012). The effect of magnesium supplementation on primary insomnia in elderly: a double-blind placebo-controlled clinical trial. Journal of Research in Medical Sciences, 17(12), 1161-1169.

149. Nobre, A. C., Rao, A., & Owen, G. N. (2008). L-theanine, a natural constituent in tea, and its effect on mental state. Asia Pacific Journal of Clinical Nutrition, 17(suppl 1), 167-168.

150. Mahlberg, R., Kunz, D., Sutej, I., Kühl, K. P., & Hellweg, R. (2009). Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. Journal of Clinical Psychopharmacology, 29(5), 456-461.

This analysis represents a synthesis of peer-reviewed research highlighting the need for comprehensive evaluation of pharmaceutical effects on neurological function. Healthcare decisions should always be made in consultation with qualified providers who can assess individual risk-benefit profiles and support safe transitions to evidence-based natural alternatives.